feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

trending

Anduril Fury makes first flight

trending

Breathlessness links to hospital mortality

trending

Google researchers propose nested learning

trending

Nvidia earnings next week

trending

WSL Football stadium design guidelines

trending

Binance BTC withdrawals signal surge

trending

Starbucks Red Cup Day arrives

trending

Christy Martin defends Sydney Sweeney

trending

Powerball jackpot at $512M

Home / Health / Cutting-Edge Gene Therapy Slashes Cholesterol by 50% with Single Dose

Cutting-Edge Gene Therapy Slashes Cholesterol by 50% with Single Dose

11 Nov

•

Summary

  • Experimental gene-editing treatment lowers LDL "bad" cholesterol and triglycerides by around 50%
  • Results sustained for at least 60 days after a single dose
  • Therapy could be "life-changing" for patients with uncontrolled high cholesterol
Cutting-Edge Gene Therapy Slashes Cholesterol by 50% with Single Dose

A cutting-edge gene-editing treatment has demonstrated the ability to dramatically slash harmful cholesterol levels by around 50% in a small clinical trial. The experimental therapy, which uses the CRISPR gene-editing tool to target a key gene in the liver, has provided significant reductions in LDL "bad" cholesterol and triglycerides for at least 60 days after a single dose.

The trial involved 15 participants from Australia, New Zealand, and the UK, all in their 50s and 60s, who had uncontrolled high cholesterol despite taking conventional medications. Researchers reported that the participants experienced a rapid drop in their cholesterol and triglyceride levels within just two weeks of receiving the treatment, with the effects sustained for at least two months.

According to the lead researcher, Dr. Steven Nissen of the Cleveland Clinic, this type of therapy could be "life-changing" for many patients struggling to manage their high cholesterol. Unlike daily pills or monthly injections, this gene-editing treatment offers a potential "one-and-done" solution that is both safe and durable. While the trial was small, the scientists are optimistic that future successful studies could pave the way for a revolutionary new approach to cholesterol management.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The CRISPR gene-editing therapy targets a gene in the liver called ANGPTL3 to lower LDL "bad" cholesterol and triglycerides, both of which are linked to heart disease.
The CRISPR therapy was able to lower cholesterol and triglyceride levels by around 50% in the 15 participants, and the results were sustained for at least 60 days after a single dose.
The 15 participants were from Australia, New Zealand, and the UK, and they were all in their 50s and 60s with uncontrolled high cholesterol despite taking conventional medications.

Read more news on

Healthside-arrowAustraliaside-arrow

You may also like

Medtronic LVAD Device Discontinued After Alarming Mortality Rates

13 hours ago • 33 reads

article image

Birmingham Hospitals Brace for Flu Surge Ahead of Winter

7 hours ago • 3 reads

article image

NHS Waiting Lists Decline for First Time in 15 Years

1 hour ago • 2 reads

article image

Doctors in England Brace for 5-Day Strike Over Pay and Training Shortages

1 hour ago • 1 read

article image

NHS Wrongly Logs Hundreds of Transgender Patients with Male Illnesses as Female

19 hours ago • 4 reads

article image